Zydus Lifesciences Overview
- Year Founded
-
1952
- Status
-
Public
- Employees
-
36,827
- Stock Symbol
-
532321
- Investments
-
35
- Share Price
-
$12.67
- (As of Friday Closing)
Zydus Lifesciences General Information
Description
Zydus Lifesciences Ltd operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products. The product portfolio of the company includes Active Pharmaceutical Ingredients [API] and human formulations. The company's operating segments are: Pharmaceuticals, Consumer Products and Medical Technologies. The majority of revenue is derived from the Pharmaceuticals segment. Geographically, it generates maximum revenue from the United States, followed by India, Europe and other countries.
Contact Information
Website
www.zyduslife.comCorporate Office
- Zydus Corporate Park, Scheme Number 63, Khoraj (Gandhinagar), 536
- Sarkhej - Gandhinagar Highway, Near Vaishnodevi Circle
- Ahmedabad, Gujarat 382481
- India
Corporate Office
- Zydus Corporate Park, Scheme Number 63, Khoraj (Gandhinagar), 536
- Sarkhej - Gandhinagar Highway, Near Vaishnodevi Circle
- Ahmedabad, Gujarat 382481
- India
Zydus Lifesciences Stock Performance
As of 13-Nov-2026, Zydus Lifesciences’s stock price is $12.67. Its current market cap is $12.6B with 998M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $12.67 | $12.87 | $9.02 - $13.36 | $12.6B | 998M | 102K | $0.45 |
Zydus Lifesciences Financials Summary
As of 30-Sep-2026, Zydus Lifesciences has a trailing 12-month revenue of $3.21B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | 13,122,200 | 9,758,721 | 10,344,493 | 12,179,400 |
| Revenue | 3,210,905 | 3,023,831 | 2,669,648 | 2,297,675 |
| EBITDA | 889,127 | 902,135 | 810,197 | 663,181 |
| Net Income | 453,035 | 570,370 | 535,200 | 466,203 |
| Total Assets | 5,789,298 | 5,554,336 | 4,349,077 | 3,511,161 |
| Total Debt | 1,454,058 | 1,324,394 | 375,640 | 96,434 |
Zydus Lifesciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Zydus Lifesciences Comparisons
Industry
Financing
Details
Zydus Lifesciences Competitors (34)
One of Zydus Lifesciences’s 34 competitors is Torrent Pharmaceuticals, a Corporation company based in Ahmedabad, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Torrent Pharmaceuticals | Corporation | Ahmedabad, India | ||||
| Mankind Pharma | Formerly PE-Backed | New Delhi, India | ||||
| Ajanta Pharma | Corporation | Mumbai, India | ||||
| Natco Pharma | Corporation | Hyderabad, India | ||||
| Glenmark Pharmaceuticals | Corporation | Mumbai, India |
Zydus Lifesciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Zydus Lifesciences Patents
Zydus Lifesciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026210504-A1 | Use of nlrp3 inhibitors for neuroprotection and neuroregeneration | Pending | 03-Apr-2025 | ||
| WO-2026163238-A1 | Improved process for the preparation of novel autotaxin inhibitor | Pending | 30-Jan-2025 | ||
| US-20260184694-A1 | Composition comprising high purity triaminopyrimidine compound and method for preparation thereof | Pending | 30-Dec-2024 | ||
| US-20260209241-A1 | Process for the preparation of benzgalantamine or a pharmaceutically acceptable salt thereof | Pending | 26-Dec-2024 | ||
| WO-2026126235-A1 | Treatment for recurrent pericarditis | Pending | 11-Dec-2024 | A61P31/12 |
Zydus Lifesciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Zydus Lifesciences Investments & Acquisitions (35)
Zydus Lifesciences’s most recent deal was a Merger/Acquisition with Zydus Sunshine Lifesciences. The deal was made on 11-Nov-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Zydus Sunshine Lifesciences | 11-Nov-2026 | Merger/Acquisition | Pharmaceuticals | ||
| Sterling Biotech (API Business Division) | 02-Nov-2026 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology | ||
| Assertio Holdings | 16-Jun-2026 | Merger/Acquisition | Pharmaceuticals | ||
| Agenus (CMC Facilities in Emeryville and Berkeley) | 01-Jan-2026 | Corporate Asset Purchase | Buildings and Property | ||
| Amplitude Surgical | 24-Oct-2025 | Secondary Transaction - Open Market | Therapeutic Devices |
Zydus Lifesciences ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
28.26 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Zydus Lifesciences Exits (4)
Zydus Lifesciences’s most recent exit was on 27-Jul-2011 from Bremer Pharma. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Bremer Pharma | 27-Jul-2011 | Completed |
|
||
| Zenex Animal Health | 14-May-2007 | Completed |
|
||
| Nippon Universal Pharmaceutical | 19-Apr-2007 | Completed |
|
||
| Zenex Animal Health | 01-Jan-2000 | Joint Venture | Completed |
|
Zydus Lifesciences Affiliates
Subsidiaries (7)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Zynext Ventures | Pennington, NJ | 2023 | |
| Sentynl Therapeutics | Solana Beach, CA | 2011 | |
| Laboratorios Combix | Madrid, Spain | 2006 | |
| Etna Biotech | Catania, Italy | 2001 | |
| Assertio Holdings | Lake Forest, IL | 1995 |
Zydus Lifesciences FAQs
-
When was Zydus Lifesciences founded?
Zydus Lifesciences was founded in 1952.
-
Where is Zydus Lifesciences headquartered?
Zydus Lifesciences is headquartered in Ahmedabad, India.
-
What is the size of Zydus Lifesciences?
Zydus Lifesciences has 36,827 total employees.
-
What industry is Zydus Lifesciences in?
Zydus Lifesciences’s primary industry is Pharmaceuticals.
-
Is Zydus Lifesciences a private or public company?
Zydus Lifesciences is a Public company.
-
What is Zydus Lifesciences’s stock symbol?
The ticker symbol for Zydus Lifesciences is 532321.
-
What is the current stock price of Zydus Lifesciences?
As of 13-Nov-2026 the stock price of Zydus Lifesciences is $12.67.
-
What is the current market cap of Zydus Lifesciences?
The current market capitalization of Zydus Lifesciences is $12.6B.
-
What is Zydus Lifesciences’s current revenue?
The trailing twelve month revenue for Zydus Lifesciences is $3.21B.
-
Who are Zydus Lifesciences’s competitors?
Torrent Pharmaceuticals, Mankind Pharma, Ajanta Pharma, Natco Pharma, and Glenmark Pharmaceuticals are some of the 34 competitors of Zydus Lifesciences.
-
What is Zydus Lifesciences’s annual earnings per share (EPS)?
Zydus Lifesciences’s EPS for 12 months was $0.45.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
